

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

Tsutomu Ohta,¹ Kumiko Iijima,^{1,5} Mamiko Miyamoto,¹ Izumi Nakahara,^{1,5} Hiroshi Tanaka,⁵ Makiko Ohtsujii,^{6,7} Takafumi Suzuki,^{6,7} Akira Kobayashi,^{6,7} Jun Yokota,² Tokuki Sakiyama,¹ Tatsuhiro Shibata,^{3,4} Masayuki Yamamoto,^{6,7} and Setsuo Hirohashi³

¹Center for Medical Genomics, ²Biology Division, ³Pathology Division, and ⁴Cancer Genomics Project, National Cancer Center Research Institute; ⁵Department of Computational Biology, Tokyo Medical and Dental University, Tokyo, Japan; ⁶Center for Tsukuba Advanced Research Alliance and Japan Science and Technology Agency-Exploratory Research for Advanced Technology Environmental Response Project, University of Tsukuba, Tsukuba, Japan; and ⁷Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract

Oxidative and electrophilic stresses are sensed by Keap1, which activates Nrf2 to achieve cytoprotection by regulating the expression of drug-metabolizing and antioxidative stress enzymes/proteins. Because oxidative and electrophilic stresses cause many diseases, including cancer, we hypothesized that an abnormality in the Nrf2-Keap1 system may facilitate the growth of cancer cells. We sequenced the *KEAP1* gene of 65 Japanese patients with lung cancer and identified five nonsynonymous somatic mutations at a frequency of 8%. We also identified two nonsynonymous somatic *KEAP1* gene mutations and two lung cancer cell lines expressing *KEAP1* at reduced levels. In lung cancer cells, low Keap1 activity (due to mutations or low-level expression) led to nuclear localization and constitutive activation of Nrf2. The latter resulted in constitutive expression of cytoprotective genes encoding multidrug resistance pumps, phase II detoxifying enzymes, and antioxidative stress enzymes/proteins. Up-regulation of these target genes in lung cancer cells led to cisplatin resistance. Nrf2 activation also stimulated growth of lung cancer-derived cell lines expressing *KEAP1* at low levels and in mutant cell lines and in *Keap1*-null mouse embryonic fibroblasts under homeostatic conditions. Thus, inhibition of *NRF2* may provide new therapeutic approaches in lung cancers with activation of Nrf2. [Cancer Res 2008;68(5):1303–9]

Introduction

Oxidative and electrophilic stresses provoke cellular adaptive responses that induce the expression of genes that encode various cytoprotective enzymes. This process is closely related to human diseases, including cancer. Among the cytoprotective gene products, phase II drug-metabolizing enzymes and antioxidative stress enzymes/proteins are encoded by genes that are regulated by a motif called the antioxidant/electrophile-responsive element (1–3). The transcription factor Nrf2 forms a heterodimer with one of the small Maf family proteins, and the complex binds to the antioxidant-responsive element to activate transcription of these

cytoprotective genes (4). Keap1 is a newly identified Nrf2-associated protein (5), containing BTB, IVR, and DGR domains (6). These domains contribute to the dual function of Keap1. Keap1 interacts specifically with an adaptor protein, Cullin 3 (Cul3), and forms an E3 ubiquitin ligase to render substrate Nrf2 susceptible to rapid degradation/turnover (7). Keap1 also functions as a sensor for electrophilic/oxidative stresses. In the absence of stress stimuli, Nrf2 is rapidly degraded through the proteasome pathway using ubiquitination by the Keap1-Cul3 E3 ligase (7). On exposure to stress, Keap1 is modified, and Nrf2 is freed from the modified Keap1, translocates into the nucleus, and activates the transcription of various cytoprotective genes (7). The rapid degradation of Nrf2 by Keap1-Cul3 E3 ligase constitutes the molecular basis for induction of cytoprotective enzymes in response to stress.

Nrf2-deficient mice are susceptible to electrophilic/oxidative stresses due to impaired expression of cytoprotective enzymes/proteins (8). This observation strongly supports the essential contribution of Nrf2 to both basal and inducible expression of cytoprotective enzymes and suggests new possibilities for environmental response studies (9). Similarly, Keap1-deficient mice constitutively express cytoprotective and antioxidant enzymes/proteins (10), indicating that the Nrf2-Keap1 system functions physiologically for cytoprotection against environmental stresses. The ubiquitin proteasome system using Cullin-type E3 ligases shares a similar role in critical stress responses. For instance, the transcription factors I κ B (11) and hypoxia-inducible factor-1 α (12) use Cul1 and Cul2, respectively, to form specific E3 ligases. Inhibition of rapid turnover/repression is a common (and evolutionarily ancient) strategy animals have acquired for rapid responses to environmental changes.

To our surprise, however, we identified somatic mutations in the *KEAP1* gene of Japanese patients with lung cancer and in lung cancer cell lines (13). These *KEAP1* mutations affected the repressive activity of Keap1, stimulated nuclear accumulation of Nrf2, and induced constitutive expression of cytoprotective enzymes within the cancer cells. More recently, somatic mutations in *KEAP1* were detected in 19% of Caucasian patients with lung cancer (14). Collectively, these observations suggest that the Nrf2-Keap1 pathway acts as a double-edged sword: it protects the body from chemical carcinogenesis but aids the growth and development of cancer cells (13). To examine the characteristics of *KEAP1* mutations further and to address whether they provide selective advantages for cancer progression, we analyzed the expression and mutation of the *KEAP1* gene in samples from Japanese patients with lung cancer and in established lung cancer cell lines. We

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Requests for reprints: Tsutomu Ohta, Center for Medical Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-3248-1631; E-mail: cota@gan2.res.ncc.go.jp.

©2008 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-5003

Table 1. *KEAP1* alterations in lung cancer tissues and cell lines

Patients/cell lines	Pathology	Amino acid change	Domain
P1	SCC	A427V (heterozygous)	DGR
P9	ADC	H200P (heterozygous)	IVR
P12	ADC	G430C (heterozygous)	DGR
P23	ADC	R415G (heterozygous)	DGR
P65	LCC	G476R (homozygous)	DGR
H2126	ADC	R272C (homozygous)	IVR
H1648	ADC	G364C (homozygous)	DGR

Abbreviations: SCC, small cell carcinomas; ADC, adenocarcinomas; LCC, large cell carcinomas.

identified the molecular basis of these loss-of-function type somatic mutations in patients with lung cancer and found that they provided advantages to lung cancer cells.

Materials and Methods

Tissue samples and cell lines. Tumor tissues were obtained with informed consent from patients who received surgical treatment at the National Cancer Center Hospital. Lung cancer cell lines SQ-19, H2126, H1437, H1395, and A549 were obtained from the American Type Culture Collection; II-18 was obtained from Riken Bio Resource Center; and RERF-LC-MS was obtained from the Japanese Collection of Research Bioresources Cell Bank. All cell lines were maintained in DMEM with 10% calf serum, 10% fetal bovine serum (FBS), or 20% FBS containing F-12 nutrient mixture. Mouse embryonic fibroblasts (MEF) were prepared from individual embryos at embryonic day 13.5. The head and internal organs were removed, and the torso was minced and dispersed in 0.25% trypsin/EDTA. MEFs were maintained in DMEM containing 10% FBS. Briefly, MEFs at less than five passages were used as early-passage primary MEFs. To immortalize MEFs, the fibroblasts were cultured continuously until the fibroblasts started growing rapidly. Immortalization of the primary MEFs was usually observed after 25 passages.

Sequencing of *KEAP1*. DNAs extracted from cancer tissues and cell lines were amplified according to a ligation-mediated PCR method using a high-fidelity DNA polymerase, KOD Plus, and were used for sequencing (15). PCR primers were designed to amplify every exon plus ~100 bases flanking each exon. Reference sequence of the *KEAP1* gene was retrieved from public database Genbank.⁸ Sequencing was performed using the following primer sets: exon 2, 5'-TGCAATGGATTCTGCTTCACCTACTTTTGCAGGAA-3' (forward) and 5'-TGAGCCCAGAACCTCCTTTTCTCCAGTTTC-3' (reverse); exon 3, 5'-TATTTGAATCCCCATTAGCAGATAAGGAAGCTGA-3' (forward) and 5'-TAGAACTCTCAAGGAGCTTAGCTTCATCCTGAG-3' (reverse); exon 4, 5'-ATGAGCCATCGCGCCGGATGAACCTGTCTTTAA-3' (forward) and 5'-CTCTATCAGAATCCAGGGCTCTGTGTTA-3' (reverse); exon 5, 5'-TTC-TGAGGGTGAGAAGGGAGAGGAGAGAGGAAA-3' (forward) and 5'-AGCTGGCAACAGAGCGAGACCTTGTCTTAA-3' (reverse); and exon 6, 5'-TGCC-TCAGCCCTGCAAAGTGCTAGGATTATAGG-3' (forward) and 5'-CTTTGGACTCTTTTGTAGATGTCATTTAACTG-3' (reverse).

Plasmid construction and reporter assay. Flag-tagged *KEAP1* and its mutations were inserted in pCMV-tag2A (Stratagene). Transfections of expression vectors, the luciferase reporter pRBGP2 containing three copies of Nrf2-binding element (16), and pRL-TK were carried out using Lipofectamine Plus Reagent (Invitrogen). After 36 h of transfection, the cells in 24-well plates were washed by PBS and analyzed for luciferase

activities in triplicate in each transfection experiment using Dual-Luciferase Reporter Assay System (Promega). All experiments were repeated at least thrice.

Immunoprecipitation, immunofluorescence, and *in vivo* ubiquitination assays. Immunoprecipitation, immunofluorescence microscopy, and *in vivo* ubiquitination assays were performed as described previously (7).

Real-time PCR. Total RNAs were isolated from cell lines by Trizol reagent (Invitrogen). First-strand cDNAs were obtained from total RNA (5 µg) by SuperScript First-Strand Synthesis System (Invitrogen). Real-time PCR was performed by ABI 7000 (Applied Biosystems) using the following primer sets: *KEAP1*, 5'-TACGATGTGGAAACAGAGACGTGGACTTTCGTA-3' (forward) and 5'-TCAACAGGTACAGTTCTGGTCAATCTGCTT-3' (reverse); *NADPH dehydrogenase quinone 1 (NQO1)*, 5'-AGGAAGAGCTAATAAATCTCTTCTTGCTG-3' (forward) and 5'-TCATATTGCAGATGTACGGTGTG-GATTTAT-3' (reverse); *multidrug resistance protein 3 (MRP3)*, 5'-GAC-CATCGCACACCGGCTTAACACTATCATGGA-3' (forward) and 5'-TCAGTA-CTCCATTTTAAATGGATTCAGGCAGCA-3' (reverse); and *PRDX1*, 5'-AA-GTGATTGGTGTCTTGTGGATTCTCACT-3' (forward) and 5'-TCAC-TTCTGCTGGAGAAATATTCTTTGCTC-3' (reverse). *GAPD* gene was used as an internal control. Reverse transcription-PCR (RT-PCR) was performed using primer sets as same as real-time PCR.

Small interfering RNA and cell growth analysis. For the small interfering RNA (siRNA) experiments, 20 nmol/L of control siRNA (Qiagen) and *NRF2*-specific siRNA (SI03246950; Qiagen) were used. Transfection was performed as described previously (17). RT-PCR was performed after 3 days and cell numbers were counted after 7 days.

Results and Discussion

To explore somatic mutations in *KEAP1* genes of lung cancer patients, we designed a sequencing system for protein-coding





Figure 1. Structural alterations of *KEAP1* in lung cancer. **A**, *KEAP1* contains NH₂-terminal BTB, central IVR, and COOH-terminal DGR domains. Numbers, amino acid positions; asterisks, position of the identified mutations of *KEAP1* in lung cancer cases. **B**, sequences of *KEAP1* mutations at the IVR and DGR domains in lung cancer tissues and cell lines. **N**, *KEAP1* sequence of normal tissue; **T**, *KEAP1* sequence of tumor tissue or cancer cell line. **C**, mutation positions at IVR and DGR domains of human (H), mouse (M), and rat (R) in *Keap1*. Red letters, amino acids of the identified mutations of *KEAP1* in lung cancer; blue letters and numbers, amino acid and its positions of normal *KEAP1*.

⁸ <http://www.ncbi.nlm.nih.gov/>

Figure 2. Molecular effects of *KEAP1* mutations. **A**, subcellular localizations of Keap1 mutants and EGFP-fused Nrf2. Nrf2-GFP was transfected into NIH3T3 cells with Flag-tagged Keap1 or its mutant, and their subcellular localizations were examined by EGFP fluorescence and immunohistochemical staining with anti-Flag antibody. DAPI, 4',6-diamidino-2-phenylindole. **B**, association activity of Keap1 mutants with Nrf2. Expression plasmid for HA-Nrf2 and Flag-Keap1 WT (lane 1) or mutants (lanes 2–5) transfected into NIH3T3 cells. Flag-tagged Keap1 or its mutants were immunoprecipitated from whole-cell lysates (*Inp*) using anti-Flag antibody M2-conjugated agarose (*IP* with α -Flag). **C**, repression activity of Keap1 mutants against Nrf2. Expression plasmid for Nrf2 and Keap1 WT (lane 3) or Keap1 mutants (lanes 4–7) was transfected into NIH3T3 cells with pRBGP2 reporter plasmid. The activity in the absence of WT *KEAP1* and its mutant was set at 100. **D**, dominant-negative activity of R415G or G430C *KEAP1* mutation on Nrf2 transactivation by luciferase activity. Expression plasmid (100 ng) for Nrf2 and pRBGP2 reporter plasmid was transfected into NIH3T3 cells with WT *KEAP1* (10 ng; lanes 2–8), R415G mutant (5, 10, or 20 ng; lanes 3–5), or G430C mutant (5, 10, or 20 ng; lanes 6–8). The activity in the absence of WT and mutant *KEAP1* was set at 100.



exons and exon-intron boundaries of the gene. Exploiting this system, we sequenced *KEAP1* genes of primary lung cancer tissues from 65 Japanese patients, including 29 with adenocarcinoma, 26 with squamous cell carcinoma, 8 with small cell carcinoma, and 2 with large cell carcinoma (Supplementary Table S1). We identified five somatic mutations associated with amino acid changes (Table 1; Fig. 1), indicating that ~8% (5 of 65) of Japanese lung cancer patients had a somatic mutation in the protein. In this analysis, we also found two somatic mutations in the intron region (data not shown).

Mutations in the *KEAP1* gene were detected frequently (10%; 3 of 29) in Japanese lung adenocarcinoma cases (Table 1). In a study of Caucasian (14), *KEAP1* somatic mutations were detected in 19% (10 of 54) of all lung cancer cases and in 26% (9 of 35) of adenocarcinoma cases. Thus, our present results indicate a high incidence/frequency of *KEAP1* somatic mutations in patients with lung adenocarcinoma independent of the patients' geographic origin. Whereas the alterations in Caucasians were composed of four missense point mutations and six deletion/insertion mutations, all of the mutations found in the current study were missense mutations. Thus, the frequency of *KEAP1* missense mutations in Japanese lung adenocarcinoma cases (3 of 29) is very similar to that in Caucasians (4 of 35). Because no deletion/insertion mutations in *KEAP1* were identified in Japanese lung adenocarcinoma cases, further exploration of the *KEAP1* mutations in Japanese lung cancer cases is necessary. We also identified amino acid changes as

homozygous gene mutations in *KEAP1* in one cancer tissue and in two lung cancer-derived cell lines (Table 1). Microsatellite-based genotyping of lung cancer tissues showed loss of heterozygosity (LOH) at 19p13.2 (containing the *KEAP1* gene locus) in 41% of cases (14), suggesting that the homozygous gene mutations that we identified (Table 1; Fig. 1B) might contain LOH at the *KEAP1* gene locus.

All of the mutations identified in this study were located within the IVR and DGR domains of Keap1 (Table 1; Fig. 1A). The IVR domain is responsible for the ubiquitination of Nrf2 (7), and the DGR domain interacts with Nrf2 (5). To examine the molecular defects caused by these mutations, we asked whether mutant Keap1 has the ability to interact with Nrf2 and sequester it in the cytoplasm. To this end, we transfected enhanced green fluorescent protein (EGFP)-fused Nrf2 (Nrf2-GFP) with a Flag-tagged Keap1 mutant into NIH3T3 cells and examined the cellular localization of GFP. We also used an immunohistochemical procedure with an anti-Flag antibody. Nrf2-GFP accumulated in the cytoplasm in wild-type (WT) Keap1 and Keap1 H200P mutant cells. In contrast, Nrf2-GFP accumulated in the nucleus (Fig. 2A) on cotransfection with R415G or G430C mutants (13), indicating that the latter two mutants lost their ability to bind and sequester Nrf2 in the cytoplasm. In the case of the R272C mutant, Nrf2 resided both in the cytoplasm and in the nucleus (Fig. 2A).

To elucidate whether these Keap1 mutants interacted physically with Nrf2, we performed an immunoprecipitation analysis. When




Figure 3. Molecular effects of R272C *KEAP1* mutation. **A**, Nrf2 degradation activity of Keap1 and its mutants. Expression plasmid (100 ng) for HA-Nrf2 and Flag-Keap1 (*lanes 1 and 2*) or Keap1 mutants (*lanes 3 and 4*) was transfected into NIH3T3 cell. Twenty-four hours after transfection, cells were treated with (*lanes 1 and 3*) or without (*lanes 2 and 4*) MG132 (2 $\mu\text{mol/L}$) for 12 h. HA-Nrf2 and Flag-Keap1 or its mutants in whole-cell lysates were examined by anti-HA (Nrf2) and anti-Flag (Keap1) antibodies. **B**, association activity of Keap1 R272C mutant with Cul3. Expression plasmid (100 ng) for HA-Cul3 and Flag-Keap1 (*lane 1*) or R272C mutant (*lane 2*) was transfected into 293T cells. HA-Cul3 was immunoprecipitated from whole-cell lysates (*Input*) using anti-HA antibody and precipitants were analyzed by anti-Flag antibody M2-conjugated agarose (*IP with α -HA*). **C**, ubiquitination of Nrf2 by Keap1 and R272C mutant. Expression plasmid (1 μg) for HA-Nrf2 and Flag-Keap1 WT (*lane 1*), Keap1 R272C mutant (*lane 2*), or empty vector (*lane 3*) was transfected into 293T cells with His-tagged ubiquitin (*Ub*; 3 μg). HA-Nrf2 was immunoprecipitated from whole-cell lysates using anti-HA antibody and ubiquitinated Nrf2 (*Nrf2-Ub*) was analyzed by anti-His antibody. **D**, nuclear localization of Nrf2 in lung cancer cell line with R272C mutation. Nrf2 in H2126 (R272C mutant) cells was stained by anti-Nrf2 antibody. Nrf2 signals (*green*) were observed within the nucleus and the cytoplasm.

Flag-tagged Keap1 or Keap1 mutants were transfected into NIH3T3 cells concomitant with hemagglutinin (HA)-tagged Nrf2, WT Keap1 and Keap1 H200P and R272C mutants (Fig. 2*B*, *lanes 1–3*) were immunoprecipitated with Nrf2 by an anti-Flag antibody. In contrast, Nrf2 was not coimmunoprecipitated efficiently with Keap1 R415G and G430C mutants (Fig. 2*B*, *lanes 4 and 5*). These results are consistent with the subcellular localization analysis and show that R415G and G430C mutants in the DGR domain impair the association of Keap1 with Nrf2.

To examine how those Keap1 mutations affected the repressive activity of Keap1 against Nrf2, we performed a reporter cotransfection-transactivation analysis. Keap1 or individual Keap1 mutants were cotransfected into NIH3T3 cells with an Nrf2 expression plasmid and a luciferase reporter pRBGP2 (16). Luciferase activity was repressed significantly when WT Keap1 or the H200P mutant was transfected simultaneously (Fig. 2*C*, *lanes 3 and 4*). We did not detect any effects of the H200P mutant. In contrast, cotransfection of R272C, R415G, or G430C mutants (Fig. 2*C*, *lanes 5–7*) had no effect on luciferase reporter activity, suggesting that the latter three mutations affected the capacity of Keap1 to repress Nrf2. Significantly, the loss of repressive activity in R415G and G430C mutants correlated well with the loss of interaction with Nrf2.

Because we identified R415G and G430C mutants as heterozygous gene mutations in lung cancer, we asked whether the Keap1 mutant affected WT Keap1 activity. Toward that end, pRBGP2 reporter activity was examined in NIH3T3 cells after cotransfection with WT Keap1 and graded doses of the R415G or G430C mutants. The repressive activity of WT Keap1 decreased with increments of

the R415G or G430C mutants (Fig. 2*D*, *lanes 3–8 and 6–8*), suggesting that these mutants repressed WT Keap1 in a dominant-negative manner. Thus, heterozygous mutation of *KEAP1* can also activate Nrf2 through its dominant-negative function. In this regard, it is interesting to note the recently proposed two-site substrate recognition model for Keap1-Nrf2 interaction (18). In this model, one Keap1 homodimer associates with two sites of Nrf2, and this interaction is essential for ubiquitination of Nrf2, and we surmise that the R415G or G430C mutant dimerizes with WT Keap1 to form a nonfunctional Keap1 heterodimer.

In contrast to the R415G and G430C mutants, the R272C mutant retained binding activity to Nrf2 but lost Nrf2 repressive activity (Fig. 2*A–C*). We hypothesized that this mutant in IVR might impair Nrf2 degradation, as the IVR domain of *KEAP1* is responsible for the degradation of Nrf2 (7). To test this hypothesis, we expressed Nrf2 and WT Keap1 or the R272C mutant in NIH3T3 cells, and the stability of Nrf2 protein was determined. Whereas the Nrf2 level was very low in the cells cotransfected with WT Keap1, treatment of cells with the proteasome inhibitor MG132 stabilized the Nrf2 protein (Fig. 3*A*, *lanes 1 and 2*). The Nrf2 level in cells cotransfected with the R272C mutant was very high and was not induced effectively by MG132 (Fig. 3*A*, *lanes 3 and 4*). These results indicate that the R272C mutant impaired Nrf2 degradation.

To determine whether the R272C mutant binds Cul3 in the cells, we then performed an immunoprecipitation analysis. When Flag-tagged Keap1 or the R272C mutant was transfected with HA-tagged Cul3 into 293T cells, Cul3 was coimmunoprecipitated with both the WT Keap1 and the R272C mutant (Fig. 3*B*, *lanes 1 and 2*), indicating that R272C binds to Cul3 as WT Keap1 does. We also

performed an *in vivo* ubiquitination analysis to determine how the R272C-Cul3 complex contributed to ubiquitination of Nrf2. For this purpose, either Flag-tagged WT Keap1 or the R272C mutant was transfected into 293T cells concomitant with HA-tagged Nrf2 and His-tagged ubiquitin, and HA-Nrf2 was immunoprecipitated by an anti-HA antibody. Nrf2 ubiquitination was detected by immunoblot analysis with an anti-histidine antibody. Nrf2 ubiquitination was stimulated significantly by WT Keap1 (Fig. 3C, lane 1) but not by the R272C mutant (Fig. 3C, lane 2). We previously found that Cys²⁷³ and Cys²⁸⁸ of Keap1 are essential for the ubiquitination of Nrf2 (7). Therefore, we speculated that the association between the R272C mutant and Cul3 may be inadequate for the ubiquitination of Nrf2.

The molecular basis by which the R272C mutant lost the capacity to degrade Nrf2 is unclear. However, further studies in this area should help elucidate the mechanism by which Keap1-Cul3 E3 ligase degrades Nrf2. In this regard, it is interesting to note that endogenous Nrf2 is located in the nucleus of H2126 cells harboring the R272C mutation, even in the absence of stress stimuli (Fig. 3D), suggesting that the stabilized Nrf2 protein could enter the nucleus in homeostatic conditions.

Next, we used real-time PCR to analyze the expression level of the *KEAP1* gene in primary lung cancer tissues and normal tissues from adenocarcinoma patients. We found lower levels of expression of *KEAP1* in cancer tissue (Fig. 4A, P#4). We next analyzed the

expression level of the *KEAP1* gene in six lung cancer cell lines by real-time PCR and found a reduction of *KEAP1* gene expression in two lung adenocarcinoma cell lines, H1437 and II-18 (Fig. 4B, lanes 2 and 5). These observations imply that reduced expression of the *KEAP1* gene may occur frequently in lung cancer, as is the case for the somatic mutations. To examine the subcellular localization of Nrf2 in cells expressing lower levels of *KEAP1*, we identified endogenous Nrf2 using confocal laser scanning microscopy. We found that endogenous Nrf2 was localized in the nuclei of H1437, II-18, and A549 (G333C; ref. 14) cells with the *KEAP1* mutation (Fig. 4C). However, it was not located in the nuclei of SQ-19 cells with normal *KEAP1* (Fig. 4C). Showing very good agreement, high-level expression of the two target genes, *NQO1* (19) and *MRP3* (20), was detected by real-time PCR analysis in H1437, II-18, and A549 cells but not in SQ-19 cells (Supplementary Fig. S1B). This result correlated with the expression of the two target genes, *NQO1* and *MRP3*, in cancer tissues expressing *KEAP1* at lower levels (Supplementary Figs. S1A and S4A). Expression levels of *NQO1* and *MRP3* were decreased by transfection of WT *KEAP1* gene into II-18 and A549 cells (data not shown). These results show that loss of Keap1 activity in these cells consistently enhanced the nuclear accumulation of Nrf2 and contributed to the increased expression of cytoprotective enzymes/proteins.

Because Nrf2 induces detoxifying enzymes and multidrug-resistant pumps, cell lines expressing lower levels of *KEAP1*




Figure 4. Low-level expression of *KEAP1* in lung cancer cells provides advantages to lung cancer cell progression. **A**, expression of *KEAP1* gene in normal lung tissues and lung cancer tissues. The *KEAP1* expression levels of normal lung tissues (N) and lung cancer tissues (T) from five Japanese patients with adenocarcinomas (P#1 to P#5) were analyzed by real-time PCR. Level of *KEAP1* gene expression in each normal tissue was set at 1.0. *GAPD* gene was used as an internal control. **B**, expression of *KEAP1* gene of six lung cancer cell lines. The expression levels of the cell lines RERF-LC-MS (lane 1), II-18 (lane 2), SQ-19 (lane 3), A549 (lane 4), H1437 (lane 5), or H1395 (lane 6) were analyzed by real-time PCR. Level of *KEAP1* gene expression in RERF-LC-MS cell line was set at 1.0. *GAPD* gene was used as an internal control. **C**, nuclear localizations of Nrf2 in lung cancer cell lines with *KEAP1* lower expression and mutation. Nrf2 in SQ-19 (normal *KEAP1*), II-18 (low expression of *KEAP1*), H1437 (low expression of *KEAP1*), or A549 (C333A mutant of *KEAP1*) cells was stained by anti-Nrf2 antibody. Nrf2 signals (green) were observed within the nucleus with a punctuate pattern and in regions with little blue 4',6-diamidino-2-phenylindole signal in II-18, H1437, and A549 cells but not in SQ-19 cells. **D**, Nrf2-mediated gene expression provides drug resistance in lung cancer cell lines. SQ-19, II-18, H1437, or A549 cells were exposed to incremental amounts of cisplatin (0, 3, 6 and 12 μmol/L), and after 10 d, viable cells were determined. Data are presented as percentage of viable cells relative to the DMSO-treated control cells.




Figure 5. The activated Nrf2 actually provides growth advantages to the lung cancer cells under homeostatic condition. **A**, knockdown of *NRF2* expression by *NRF2*-specific siRNA. The control siRNA (lanes 1, 3, 5, 7, 9, 11, 13, 15, and 17) or the siRNA specific for *NRF2* (lanes 2, 4, 6, 8, 10, 12, 14, 16, and 18) was transfected into SQ-19 (lanes 1, 2, 7, 8, 13, and 14), II-18 (lanes 3, 4, 9, 10, 15, and 16), and A549 (lanes 5, 6, 11, 12, 17, and 18) cells. Three days after transfection, cells were collected. The expression levels of *NRF2*, *NQO1*, and *MRP3* in the cells were analyzed by real-time PCR. **B**, knockdown of *NRF2* expression by *NRF2*-specific siRNA decreased the growth rate of *KEAP1* mutation or lower-expression cells. The control siRNA or the siRNA specific for *NRF2* was transfected into SQ-19 (lanes 1 and 2), II-18 (lanes 3 and 4), and A549 (lanes 5 and 6) cells as same as in **A**. Seven days after transfection, cells were collected and counted. **C**, *Keap1* deletion increases the growth rate of immortalized MEF cells. Immortalized MEF (*KEAP1*^{+/+}, *Keap1*^{+/+}, and *Keap1*^{-/-}) cells were plated at 0.5×10^4 per 35-mm dish and incubated. At the indicated time points, the cells were removed from the plates with trypsin and counted. The average numbers of cells at each time point were determined, and their standard deviations were obtained and plotted.

should show resistance to chemotherapy reagents. To test this possibility, we analyzed the sensitivity of these cell lines to cisplatin. Cell viability was measured 10 days after exposure to various concentrations of cisplatin. We found that cell lines expressing lower levels of *KEAP1* (H1437 and II-18) and *KEAP1* mutant cells (A549) showed greater resistance to cisplatin than SQ-19 cells with normal *KEAP1* (Fig. 4D), indicating that constitutive activation of Nrf2 enhances resistance to chemotherapy reagents.

Another intriguing possibility is that the constitutive activation of Nrf2 in cancer cells may confer selective growth advantages to cancer cells. Indeed, an Nrf2 target gene, *PRDX1* (21), enhances cell growth and radioresistance in the lung cancer cell line A549 (22), which harbors a mutation in the *KEAP1* gene (14). We therefore used real-time PCR to determine the *PRDX1* expression level in cell lines expressing lower levels of *KEAP1*. We found that it was higher in H1437, II-18, and A549 cells than in SQ-19 cells (Supplementary Fig. S1B). These results support the notion that some of the Nrf2 target genes in lung cancer cells may enhance cancer cell growth. Therefore, to determine whether knockdown of *NRF2* expression affects the growth of cancer cells with *KEAP1* mutation or reduced expression, we analyzed cell growth for 7 days after transfection of SQ-19 cells (*KEAP1* normal), II-18 cells (low expression of *KEAP1*), and A549 cells (*KEAP1* mutation) with *NRF2*-specific siRNA. We found that knockdown of *NRF2* expression (Fig. 5A, lanes 1–6)

reduced expression of its target genes (Fig. 5A, lanes 9–12 and 15–18) and induced growth inhibition (Fig. 5B, lanes 3–6) of II-18 and A549 cells but not of SQ-19 cells [Fig. 5A, lanes 7, 8, 13 and B 1 and 2]. These results suggest that activation of Nrf2 through reduced Keap1 activity, either through mutation or reduced expression, provides growth advantages to lung cancer cells under homeostatic conditions. To further examine the advantages of cancer cells harboring the *KEAP1* mutation, we studied the growth of *Keap1*^{-/-} MEFs. Both *KEAP1*^{+/+} and *Keap1*^{-/-} MEFs grew at similar rate during the first few passages (Supplementary Fig. S2). However, following spontaneous immortalization of MEF cells and after several passages, *Keap1*^{-/-} cells grew faster than *KEAP1*^{+/+} and *Keap1*^{+/+} cells (Fig. 5C). This result supports our contention that reduced Keap1 activity facilitates cell growth. The molecular basis of activated Nrf2-stimulated cell growth is unclear. Thus, further exploration of Nrf2 activation and its effect on cancer cell growth is necessary.

In summary, we identified somatic mutations of *KEAP1* and low-level expressions of *KEAP1* in lung cancer tissues and cell lines. These results indicate a high incidence/frequent occurrence of loss of Keap1 function in patients with lung cancer. The loss of Keap1 function enhanced the nuclear accumulation of Nrf2 and elevated the expression of antioxidative and antixenobiotic stress enzymes and drug efflux pumps, suggesting that cancer cells with weakened Keap1 function acquire multiple advantages for proliferation.

Therefore, disruption of *NRF2* by specific inhibitors may provide new therapeutic approaches against lung cancers with high Nrf2 activity.

Acknowledgments

Received 8/23/2007; revised 11/26/2007; accepted 12/20/2007.

Grant support: Grants-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare; for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; for Genome Network Project; for

promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research, Ministry of Education, Culture, Sports, Science and Technology; and for Japan Science and Technology Agency-Exploratory Research for Advanced Technology Environmental Response Project.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Teruhiko Yoshida [National Cancer Center Research Institute (NCCRI), Tokyo, Japan], Misao Ohki (NCCRI), Takashi Kohno (NCCRI), and Susumu Hirose (National Institute of Genetics, Shizuoka, Japan) for valuable suggestions and Reiko Odagawa, Sachiko Mimaki, and Go Maeno (NCCRI) for technical support.

This study protocol was reviewed and approved by the institutional review board of the National Cancer Center.

References

- Hayes JD, Chanas SA, Henderson CJ, et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione *S*-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. *Biochem Soc Trans* 2000;28:33–41.
- Itoh K, Ishii T, Wakabayashi N, Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. *Free Radic Res* 1999;31:319–24.
- Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu Rev Pharmacol Toxicol* 2003;43:233–60.
- Motohashi H, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. *Proc Natl Acad Sci U S A* 2004; 101:6379–84.
- Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev* 1999;13:76–86.
- Adams J, Kelso R, Cooley L. The kelch repeat superfamily of proteins: propellers of cell function. *Trends Cell Biol* 2000;10:17–24.
- Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. *Mol Cell Biol* 2004;24:7130–9.
- Itoh K, Takahashi S, Ishii T, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 1997;236: 313–22.
- Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. *Proc Natl Acad Sci U S A* 1999;96:12731–6.
- Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. *Nat Genet* 2003;35: 238–45.
- Amit S, Ben-Neriah Y. NF- κ B activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. *Semin Cancer Biol* 2003;13:15–28.
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. *J Clin Oncol* 2004;22:4991–5004.
- Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. *Mol Cell* 2006;21:689–700.
- Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. *PLoS Med* 2006;3:e420.
- Sakiyama T, Kohno T, Mimaki S, et al. Association of amino acid substitution polymorphisms in DNA repair genes, TP53, POLI, REV1 and LIG4, with lung cancer risk. *Int J Cancer* 2005;114:730–7.
- Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. *Nature* 1994;367:568–72.
- Ishida M, Miyamoto M, Naitoh S, et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. *Mol Cell Biol* 2007;27:1348–55.
- Tong KI, Kobayashi A, Katsuoka F, Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. *Biol Chem* 2006;387:1311–20.
- Jaiswal AK, McBride OW, Adesnik M, Nebert DW. Human dioxin-inducible cytosolic NAD(P)H: menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. *J Biol Chem* 1988;263:13572–8.
- Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. *Hum Mol Genet* 1996;5:1649–55.
- Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. *Cancer Res* 2007;67:546–54.
- Chen MF, Keng PC, Shau H, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. *Int J Radiat Oncol Biol Phys* 2006;64:581–91.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

Tsutomu Ohta, Kumiko Iijima, Mamiko Miyamoto, et al.

Cancer Res 2008;68:1303-1309.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/68/5/1303>

Supplementary Material Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2008/02/28/68.5.1303.DC1>

Cited articles This article cites 22 articles, 9 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/5/1303.full#ref-list-1>

Citing articles This article has been cited by 70 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/68/5/1303.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/68/5/1303>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.